PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma

Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation

Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
2021-04-08
(Press-News.org) Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.

The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children's Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children's Cancer Program and OSF Children's Hospital of Illinois.

A paper detailing the findings was published today in the Journal of Clinical Oncology.

A new kind of therapy Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.

"I think of brentuximab vedotin as a smart drug," said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. "Unlike conventional chemotherapy, which can have wide-ranging effects on all cells of the body, this drug knows to go directly to the Hodgkin lymphoma cells - maximizing its effect while minimizing side effects."

This phase 2 clinical trial replaced the chemotherapy drug vincristine with brentuximab vedotin in the frontline (first therapy given) treatment regimen. The regimen included other chemotherapy agents and radiation when needed. Vincristine is associated with neuropathy. Removing it from the regimen resulted in patients reporting a reduction in this symptom.

Overall three-year survival for the trial was 99%. Of the 77 patients enrolled in the study, 35% were spared radiation. When radiation was needed, it was precisely tailored, and doses were reduced when possible.

"We have already reduced the use of radiation for low-risk Hodgkin lymphoma patients. In this study we've shown that it is also possible to either omit or reduce the extent of radiation for high-risk patients, using highly focal methods such as proton beam radiation or intensity modulated radiation," said co-senior author Matthew Krasin, M.D., St. Jude Department of Radiation Oncology.

The researchers concluded that brentuximab vedotin in the frontline treatment of pediatric high-risk Hodkgin lymphoma is tolerable, reduced radiation exposure and produced excellent outcomes. Brentuximab vedotin is currently being incorporated into other national trials for the care of pediatric patients with Hodgkin lymphoma.

"Being able to offer Hodgkin lymphoma patients a targeted therapy in the frontline setting is an exciting development," said co-senior author Melissa Hudson, M.D., St. Jude Cancer Survivorship Division director. "We are constantly learning from research and applying new findings to the next iteration of clinical trials."

INFORMATION:

The study's authors include Michael Link, Susan Hiniker and Sarah Donaldson, Stanford University School of Medicine; Amy Billett, Nemours/Alfred I. DuPont Hospital for Children (formerly Dana-Farber Cancer Institute); Torunn Yock and Alison Friedmann, Massachusetts General Hospital; Sandra Luna-Fineman, University of Colorado (formerly Stanford University); Eric Larson, Maine Children's Cancer Program; and Pedro de Alarcon, OSF Children's Hospital of Illinois. Other St. Jude authors are Jamie Flerlage, John Lucas Jr., Belinda Mandrell, Matthew Ehrhardt, Nickhill Bhakta, Sue Kaste, Barry Shulkin, Zhaohua Lu and Chen Li.

The study was a multi-center, investigator-initiated, single-arm trial sponsored by Seattle Genetics (IND (#118603). The research at St. Jude was funded in part by grants from the National Cancer Institute (P30CA021765), and ALSAC, the fundraising and awareness organization of St. Jude.


[Attachments] See images for this press release:
Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma

ELSE PRESS RELEASES FROM THIS DATE:

A protein with a dual role: Both repair and mutation

A protein with a dual role: Both repair and mutation
2021-04-08
The Mfd protein repairs bacterial DNA, but can also, to scientists' surprise, promote mutation. Bacterial mutations can lead to antibiotic resistance. Understanding this second "role" of the Mfd protein opens up opportunities for combating antibiotic resistance, and also the resistance of tumours to anti-cancer drugs and therapies. Using a specialized protein, all bacteria are capable of rapidly and effectively repairing damage to their DNA from UV. However, this mutation frequency decline (Mfd) protein plays another role and causes mutations. A team involving ...

Scientists at IRB Barcelona identify a potential target to treat lung cancer

Scientists at IRB Barcelona identify a potential target to treat lung cancer
2021-04-08
In cancer, personalised medicine takes advantage of the unique genetic changes in an individual tumour to find its vulnerabilities and fight it. Many tumours have a higher number of mutations due to a antiviral defence mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations. Researchers at IRB Barcelona led by Dr. Travis Stracker and Dr. Fran Supek have found the HMCES enzyme to be the Achilles heel of some lung tumours, specifically those with a higher number of mutations caused by the APOBEC system. "We have discovered that blocking HMCES is very damaging to cells with an activated ...

Hispanic immigrants of working age at highest risk of dying from COVID-19

2021-04-08
Hispanic immigrants of working age -- 20 to 54 years old -- are over 11 times more likely to die of COVID-19 than U.S.-born men and women who are not Hispanic, according to a USC study of California death certificate data from 2020. The study, published Monday in the END ...

Carbon dots from human hair boost solar cells

2021-04-08
QUT researchers have used carbon dots, created from human hair waste sourced from a Brisbane barbershop, to create a kind of "armour" to improve the performance of cutting-edge solar technology. In a study published in the Journal of Materials Chemistry A, the researchers led by Professor Hongxia Wang in collaboration with Associate Professor Prashant Sonar of QUT's Centre for Materials Science showed the carbon nanodots could be used to improve the performance of perovskites solar cells. Perovskites solar cells, a relatively new photovoltaic technology, are seen as the best PV candidate to deliver low-cost, highly efficient solar electricity in coming years. ...

Oregon researchers identify pathway that transitions brain from plasticity to stability

Oregon researchers identify pathway that transitions brain from plasticity to stability
2021-04-08
EUGENE, Ore. -- April 8, 2021 -- Researchers exploring the developing central nervous system of fruit flies have identified nonelectrical cells that transition the brain from highly plastic into a less moldable, mature state. The cells, known as astrocytes for their star-like shapes, and associated genes eventually could become therapeutic targets, said University of Oregon postdoctoral researcher Sarah Ackerman, who led the research. "All of the cell types and signaling pathways I looked at are present in humans," Ackerman said. "Two of the genes that I ...

Third of Antarctic ice shelf area at risk of collapse as planet warms

2021-04-08
More than a third of the Antarctic's ice shelf area could be at risk of collapsing into the sea if global temperatures reach 4°C above pre-industrial levels, new research has shown. The University of Reading led the most detailed ever study forecasting how vulnerable the vast floating platforms of ice surrounding Antarctica will become to dramatic collapse events caused by melting and runoff, as climate change forces temperatures to rise. It found that 34% of the area of all Antarctic ice shelves - around half a million square kilometres - including 67% of ice shelf area on the Antarctic Peninsula, would be at risk of destabilisation under 4°C of warming. Limiting temperature ...

IU School of Medicine researchers develop blood test for depression, bipolar disorder

IU School of Medicine researchers develop blood test for depression, bipolar disorder
2021-04-08
INDIANAPOLIS--Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime. While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders, and offers a promising blood test aimed at a precision medicine approach to treatment. Led by Alexander B. Niculescu, MD, PhD, Professor of Psychiatry at IU School of Medicine, the study was published today in the high impact journal Molecular Psychiatry . The work builds on previous research conducted by Niculescu and his colleagues into blood biomarkers that track suicidality as well as pain, post-traumatic stress ...

Asteroid crater on Earth provides clues about Martian craters

Asteroid crater on Earth provides clues about Martian craters
2021-04-08
The almost 15-million-year-old Nördlinger Ries is an asteroid impact crater filled with lake sediments. Its structure is comparable to the craters currently being explored on Mars. In addition to various other deposits on the rim of the basin, the crater fill is mainly formed by stratified clay deposits. Unexpectedly, a research team led by the University of Göttingen has now discovered a volcanic ash layer in the asteroid crater. In addition, the team was able to show that the ground under the crater is sinking in the long term, which provides important ...

UofL biologists create better method to culture cells for testing drug toxicity

UofL biologists create better method to culture cells for testing drug toxicity
2021-04-08
LOUISVILLE, Ky. - When a new drug is being developed, the first question is, "Does it work?" The second question is, "Does it do harm?" No matter how effective a therapy is, if it harms the patient in the process, it has little value. Doctoral student Robert Skolik and Associate Professor Michael Menze, Ph.D., in the Department of Biology at the University of Louisville, have found a way to make cell cultures respond more closely to normal cells, allowing drugs to be screened for toxicity earlier in the research timeline. The vast majority of cells used for biomedical research are derived from cancer tissues stored in biorepositories. They are cheap to maintain, easy to grow and multiply quickly. Specifically, ...

Billboard and storefront ads for cannabis linked to problematic use in teens

Billboard and storefront ads for cannabis linked to problematic use in teens
2021-04-08
PISCATAWAY, NJ - Adolescents who frequently see billboard or storefront advertisements for recreational cannabis are more likely to use the drug weekly and to have symptoms of a cannabis use disorder, according to a new study in the Journal of Studies on Alcohol and Drugs. Despite use being illegal for those below age 21 even in states that have approved recreational marijuana, "legalization may alter the ways that youth use cannabis," write the study authors, led by Pamela J. Trangenstein, Ph.D., M.P.H., of the University of North Carolina at Chapel Hill. An increasing number of states have legalized or are considering legalizing recreational marijuana, and public concern over the risks of cannabis use has declined in recent ...

LAST 30 PRESS RELEASES:

E-cigarettes with a cigarette-like level of nicotine are effective in reducing smoking

Deep Learning model developed at UHN to maximize lifespan after liver transplant 

Convenience over reputation: Study looks at how older adults pick a doctor

Ocean bacteria release carbon into the atmosphere

Spotting cows from space

Scientists watch 2D puddles of electrons emerge in a 3D superconducting material

Research suggests SEC's increasing focus on terrorism may limit financial oversight

Plastic planet: Tracking pervasive microplastics across the globe

Gut epithelium muscles up against infection

Scientists discover three liquid phases in aerosol particles

New mechanism identified behind blindness in older adults

Common approach to diversity in higher education reflects preferences of white Americans

Study reveals cancer immunotherapy patients at most risk of life-threatening side effects

Study reveals crucial details on skin-related side effects of cancer immune therapies

Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates

Differences in B cell responses to coronaviruses and other pathogens in children and adults

Bottom-up is the way forward for nitrogen reduction at institutions

Road salts and other human sources are threatening world's freshwater supplies

Researchers engineer probiotic yeast to produce beta-carotene

Spanking may affect the brain development of a child

UConn researchers find bubbles speed up energy transfer

Antidepressant use in pregnancy tied to affective disorders in offspring; no causal link

Binge-eating is not caused by stress-induced impulsivity

Stress does not lead to loss of self-control in eating disorders

USC Stem Cell study reveals neural stem cells age rapidly

Following atoms in real time could lead to better materials design

People want to improve mental health by exercising, but stress and anxiety get in the way

More than the sum of mutations

Living foams

Research brief: How pharmacists contribute meaningfully in primary health care

[Press-News.org] Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation